Lungcellgram

Lungcellgram is an autologous bone marrow-derived mesenchymal stem cell (BM-MSC) therapy developed by Asan Medical Center for the treatment of acute respiratory distress syndrome (ARDS) and acute severe respiratory failure. The therapy involves the intravenous infusion of MSCs, which possess potent immunomodulatory, anti-inflammatory, and pro-angiogenic properties. In the lungs, these cells are thought to migrate to sites of injury, where they secrete paracrine factors that reduce the production of pro-inflammatory cytokines (such as TNF-α and IL-6), increase anti-inflammatory mediators (like IL-10), and promote the repair of the alveolar-capillary barrier. This pilot phase 2 study, known as the STELLAR trial, aims to evaluate the safety and efficacy of this approach in patients with severe respiratory failure.

Brand names

Lungcellgram

Other names

Autologous bone marrow-derived mesenchymal stem cellsBM-MSCsLungCellGram